Form 4: PBH Director Zier Receives RSU Grant

Prestige Consumer Healthcare Inc. Director Dawn M. Zier received a grant of 2,094 restricted stock units as part of the company's director compensation program.

Summary

• Dawn M. Zier, a Director of Prestige Consumer Healthcare Inc. (PBH), was granted 2,094 restricted stock units (RSUs).
• The grant, valued at $155,000, was calculated based on the closing stock price of $74.04 on August 5, 2025.
• This RSU grant is part of the Issuer's director compensation program.
• Following this transaction, Dawn M. Zier beneficially owns 16,533 shares of common stock.
• The restricted stock units are scheduled to vest on the first anniversary of the grant date.
• Settlement of the vested RSUs will occur promptly upon the earliest of the Reporting Person's death, separation from service, or a change in control of the Issuer.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive event where a director receives equity compensation, aligning interests with shareholders. This is a standard corporate governance practice and does not suggest any negative underlying issues.

Positives

• The grant of restricted stock units aligns the director's interests with long-term shareholder value.
• It demonstrates a standard practice of compensating directors with equity, which is a positive governance signal.
• The director's total beneficial ownership increased to 16,533 shares, indicating continued commitment.

Future Outlook

The restricted stock units are set to vest on the first anniversary of the grant date (August 5, 2025) and will be settled upon the earliest of the director's death, separation from service, or a change in control of the Issuer.

Industry Context

This is a routine director compensation event and does not provide specific insights into broader industry trends or competitive dynamics. It reflects standard corporate governance practices for public companies.

Comparison to Industry Standards

• The grant of restricted stock units as part of director compensation is a common practice across publicly traded companies in the U.S., aligning director incentives with shareholder interests.
• The specific value of $155,000 for an annual director equity grant is within the typical range for non-executive directors at companies of similar market capitalization to Prestige Consumer Healthcare Inc. (PBH).
• Similar grants are observed at consumer healthcare peers like Perrigo Company plc or Hims & Hers Health, Inc., where equity compensation forms a significant part of director remuneration.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to a director is a related party transaction, as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially fostering better long-term decision-making.

Next Steps

• Vesting of the 2,094 restricted stock units on the first anniversary of the grant date (August 5, 2026).
• Settlement of the vested restricted stock units upon the earliest of the director's death, separation from service, or a change in control.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director, which is an expected part of corporate governance. It does not provide new information that would fundamentally alter the investment thesis for Prestige Consumer Healthcare Inc. (PBH) or warrant a change in an existing investment position. The transaction aligns director incentives with shareholder interests but does not indicate significant operational or financial shifts.

Keywords

Prestige Consumer Healthcare, PBH, Dawn M. Zier, Director Compensation, Restricted Stock Units, RSU Grant, SEC Form 4, Equity Compensation, Corporate Governance